350 related articles for article (PubMed ID: 28160335)
1. Targeting human SET1/MLL family of proteins.
Vedadi M; Blazer L; Eram MS; Barsyte-Lovejoy D; Arrowsmith CH; Hajian T
Protein Sci; 2017 Apr; 26(4):662-676. PubMed ID: 28160335
[TBL] [Abstract][Full Text] [Related]
2. Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.
Alicea-Velázquez NL; Shinsky SA; Loh DM; Lee JH; Skalnik DG; Cosgrove MS
J Biol Chem; 2016 Oct; 291(43):22357-22372. PubMed ID: 27563068
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of nucleosome recognition and modification by MLL methyltransferases.
Xue H; Yao T; Cao M; Zhu G; Li Y; Yuan G; Chen Y; Lei M; Huang J
Nature; 2019 Sep; 573(7774):445-449. PubMed ID: 31485071
[TBL] [Abstract][Full Text] [Related]
4. Biochemical reconstitution and phylogenetic comparison of human SET1 family core complexes involved in histone methylation.
Shinsky SA; Monteith KE; Viggiano S; Cosgrove MS
J Biol Chem; 2015 Mar; 290(10):6361-75. PubMed ID: 25561738
[TBL] [Abstract][Full Text] [Related]
5. An Ash2L/RbBP5 heterodimer stimulates the MLL1 methyltransferase activity through coordinated substrate interactions with the MLL1 SET domain.
Cao F; Chen Y; Cierpicki T; Liu Y; Basrur V; Lei M; Dou Y
PLoS One; 2010 Nov; 5(11):e14102. PubMed ID: 21124902
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction.
Li DD; Wang ZH; Chen WL; Xie YY; You QD; Guo XK
Bioorg Med Chem; 2016 Nov; 24(22):6109-6118. PubMed ID: 27720555
[TBL] [Abstract][Full Text] [Related]
7. High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity.
Li DD; Chen WL; Wang ZH; Xie YY; Xu XL; Jiang ZY; Zhang XJ; You QD; Guo XK
Eur J Med Chem; 2016 Nov; 124():480-489. PubMed ID: 27598236
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for WDR5 interaction (Win) motif recognition in human SET1 family histone methyltransferases.
Dharmarajan V; Lee JH; Patel A; Skalnik DG; Cosgrove MS
J Biol Chem; 2012 Aug; 287(33):27275-89. PubMed ID: 22665483
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for activity regulation of MLL family methyltransferases.
Li Y; Han J; Zhang Y; Cao F; Liu Z; Li S; Wu J; Hu C; Wang Y; Shuai J; Chen J; Cao L; Li D; Shi P; Tian C; Zhang J; Dou Y; Li G; Chen Y; Lei M
Nature; 2016 Feb; 530(7591):447-52. PubMed ID: 26886794
[TBL] [Abstract][Full Text] [Related]
10. On the mechanism of multiple lysine methylation by the human mixed lineage leukemia protein-1 (MLL1) core complex.
Patel A; Dharmarajan V; Vought VE; Cosgrove MS
J Biol Chem; 2009 Sep; 284(36):24242-56. PubMed ID: 19556245
[TBL] [Abstract][Full Text] [Related]
11. A conserved arginine-containing motif crucial for the assembly and enzymatic activity of the mixed lineage leukemia protein-1 core complex.
Patel A; Vought VE; Dharmarajan V; Cosgrove MS
J Biol Chem; 2008 Nov; 283(47):32162-75. PubMed ID: 18829457
[TBL] [Abstract][Full Text] [Related]
12. The complex activities of the SET1/MLL complex core subunits in development and disease.
Jiang H
Biochim Biophys Acta Gene Regul Mech; 2020 Jul; 1863(7):194560. PubMed ID: 32302696
[TBL] [Abstract][Full Text] [Related]
13. A non-active-site SET domain surface crucial for the interaction of MLL1 and the RbBP5/Ash2L heterodimer within MLL family core complexes.
Shinsky SA; Hu M; Vought VE; Ng SB; Bamshad MJ; Shendure J; Cosgrove MS
J Mol Biol; 2014 Jun; 426(12):2283-99. PubMed ID: 24680668
[TBL] [Abstract][Full Text] [Related]
14. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK
Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859
[TBL] [Abstract][Full Text] [Related]
15. Development and Use of Assay Conditions Suited to Screening for and Profiling of SET-Domain-Targeted Inhibitors of the MLL/SET1 Family of Lysine Methyltransferases.
Ferry JJ; Smith RF; Denney N; Walsh CP; McCauley L; Qian J; Ma H; Horiuchi KY; Howitz KT
Assay Drug Dev Technol; 2015 May; 13(4):221-34. PubMed ID: 26065558
[TBL] [Abstract][Full Text] [Related]
16. Unique Role of the WD-40 Repeat Protein 5 (WDR5) Subunit within the Mixed Lineage Leukemia 3 (MLL3) Histone Methyltransferase Complex.
Shinsky SA; Cosgrove MS
J Biol Chem; 2015 Oct; 290(43):25819-33. PubMed ID: 26324722
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction.
Karatas H; Townsend EC; Bernard D; Dou Y; Wang S
J Med Chem; 2010 Jul; 53(14):5179-85. PubMed ID: 20575550
[TBL] [Abstract][Full Text] [Related]
18. The plasticity of WDR5 peptide-binding cleft enables the binding of the SET1 family of histone methyltransferases.
Zhang P; Lee H; Brunzelle JS; Couture JF
Nucleic Acids Res; 2012 May; 40(9):4237-46. PubMed ID: 22266653
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of benzylpiperidine inhibitors targeting the menin-MLL1 interface.
Ren J; Xu W; Tang L; Su M; Chen D; Chen YL; Zang Y; Li J; Shen J; Zhou Y; Xiong B
Bioorg Med Chem Lett; 2016 Sep; 26(18):4472-4476. PubMed ID: 27528435
[TBL] [Abstract][Full Text] [Related]
20. WRAD: enabler of the SET1-family of H3K4 methyltransferases.
Ernst P; Vakoc CR
Brief Funct Genomics; 2012 May; 11(3):217-26. PubMed ID: 22652693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
